Bicara Therapeutics’ (BCAX) “Outperform” Rating Reiterated at Wedbush

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock. Wedbush’s price objective suggests a potential upside of 72.12% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday. Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Finally, BTIG Research initiated coverage on Bicara Therapeutics in a report on Thursday. They issued a “buy” rating and a $28.00 price objective for the company. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $17.43 on Tuesday. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $19.71. The company has a market capitalization of $954.82 million, a PE ratio of -7.78 and a beta of -0.79. The business’s fifty day moving average is $16.98 and its 200 day moving average is $14.22.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, sell-side analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bicara Therapeutics news, CFO Ivan Hyep sold 17,795 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $18.55, for a total transaction of $330,097.25. Following the transaction, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,696,335.25. This represents a 10.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Raben sold 5,500 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $18.45, for a total value of $101,475.00. Following the completion of the sale, the insider directly owned 35,497 shares in the company, valued at approximately $654,919.65. The trade was a 13.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 115,852 shares of company stock worth $2,155,377 in the last ninety days.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $187,000. Tudor Investment Corp ET AL purchased a new position in Bicara Therapeutics during the third quarter valued at $296,000. Cantor Fitzgerald L. P. bought a new stake in Bicara Therapeutics in the third quarter worth $1,579,000. XTX Topco Ltd boosted its holdings in Bicara Therapeutics by 16.5% in the third quarter. XTX Topco Ltd now owns 37,774 shares of the company’s stock worth $596,000 after acquiring an additional 5,360 shares in the last quarter. Finally, Vestal Point Capital LP grew its stake in shares of Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.